Issue Date: November 9, 2009
Takeda Licenses Amylin Obesity Drugs
Takeda Pharmaceutical is licensing two obesity drugs in development at Amylin Pharmaceuticals. For a $75 million up-front payment and more than $1 billion in potential milestone payments, the Japanese firm gains access to pramlintide/metreleptin and davalintide, peptides in Phase II clinical trials as obesity treatments. Already approved to control glucose levels, pramlintide caused diabetics to lose 6 lb on average in a clinical trial. Researchers have struggled to find a safe and effective weight-loss pill. Last year, Merck & Co., Pfizer, Solvay, and Sanofi-Aventis all pulled obesity drugs from late-stage clinical studies.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society